These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 34980142)
21. Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. Gupta S; Hovelson DH; Kemeny G; Halabi S; Foo WC; Anand M; Somarelli JA; Tomlins SA; Antonarakis ES; Luo J; Dittamore RV; George DJ; Rothwell C; Nanus DM; Armstrong AJ; Gregory SG Genes Chromosomes Cancer; 2020 Apr; 59(4):225-239. PubMed ID: 31705765 [TBL] [Abstract][Full Text] [Related]
22. Evaluating liquid biopsies for methylomic profiling of prostate cancer. Silva R; Moran B; Russell NM; Fahey C; Vlajnic T; Manecksha RP; Finn SP; Brennan DJ; Gallagher WM; Perry AS Epigenetics; 2020; 15(6-7):715-727. PubMed ID: 32000564 [TBL] [Abstract][Full Text] [Related]
23. Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer. Zhao SG; Bootsma M; Zhou S; Shrestha R; Moreno-Rodriguez T; Lundberg A; Pan C; Arlidge C; Hawley JR; Foye A; Weinstein AS; Sjöström M; Zhang M; Li H; Chesner LN; Rydzewski NR; Helzer KT; Shi Y; ; Lynch M; Dehm SM; Lang JM; Alumkal JJ; He HH; Wyatt AW; Aggarwal R; Zwart W; Small EJ; Quigley DA; Lupien M; Feng FY Nat Genet; 2024 Aug; 56(8):1689-1700. PubMed ID: 39020220 [TBL] [Abstract][Full Text] [Related]
24. Development of Castration Resistant Prostate Cancer can be Predicted by a DNA Hypermethylation Profile. Angulo JC; Andrés G; Ashour N; Sánchez-Chapado M; López JI; Ropero S J Urol; 2016 Mar; 195(3):619-26. PubMed ID: 26551297 [TBL] [Abstract][Full Text] [Related]
25. Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy. Kang YJ; Jang WS; Kwon JK; Yoon CY; Lee JY; Ham WS; Choi YD BMC Cancer; 2017 Nov; 17(1):789. PubMed ID: 29169347 [TBL] [Abstract][Full Text] [Related]
26. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995 [TBL] [Abstract][Full Text] [Related]
27. [The Clinical Utility of Liquid Biopsies as Biomarkers in Metastatic Prostate Cancer]. Sumiyoshi T; Akamatsu S Gan To Kagaku Ryoho; 2021 Oct; 48(10):1203-1208. PubMed ID: 34657048 [TBL] [Abstract][Full Text] [Related]
28. Biomarkers in prostate cancer - Current clinical utility and future perspectives. Kretschmer A; Tilki D Crit Rev Oncol Hematol; 2017 Dec; 120():180-193. PubMed ID: 29198331 [TBL] [Abstract][Full Text] [Related]
29. Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. Mahon KL; Qu W; Devaney J; Paul C; Castillo L; Wykes RJ; Chatfield MD; Boyer MJ; Stockler MR; Marx G; Gurney H; Mallesara G; Molloy PL; Horvath LG; Clark SJ; Br J Cancer; 2014 Oct; 111(9):1802-9. PubMed ID: 25144624 [TBL] [Abstract][Full Text] [Related]
30. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns. De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311 [TBL] [Abstract][Full Text] [Related]
31. A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate Cancer. Heck MM; Thalgott M; Schmid SC; Oh WK; Gong Y; Wang L; Zhu J; Seitz AK; Porst D; Höppner M; Retz M; Gschwend JE; Nawroth R Prostate; 2016 Sep; 76(13):1160-8. PubMed ID: 27198487 [TBL] [Abstract][Full Text] [Related]
32. AR-V7 expression in circulating tumor cells as a potential prognostic marker in metastatic hormone-sensitive prostate cancer. Josefsson A; Damber JE; Welén K Acta Oncol; 2019 Nov; 58(11):1660-1664. PubMed ID: 31286815 [No Abstract] [Full Text] [Related]
33. [Circulating tumor cells and prostate cancer prognosis]. Capoun O; Soukup V; Mikulová V; Jančíková M; Honová H; Kološtová K; Zima T; Hanuš T Cas Lek Cesk; 2014; 153(2):72-7. PubMed ID: 24797777 [TBL] [Abstract][Full Text] [Related]
34. Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS Assays. Qiu P; Poehlein CH; Marton MJ; Laterza OF; Levitan D Sci Rep; 2019 Jan; 9(1):114. PubMed ID: 30643180 [TBL] [Abstract][Full Text] [Related]
35. Emerging promising biomarkers for treatment decision in metastatic castration-resistant prostate cancer. Kafka M; Eder IE; Klocker H; Heidegger I Urol Oncol; 2020 Nov; 38(11):801-815. PubMed ID: 32591248 [TBL] [Abstract][Full Text] [Related]
36. Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility. Pantel K; Hille C; Scher HI Clin Chem; 2019 Jan; 65(1):87-99. PubMed ID: 30602476 [TBL] [Abstract][Full Text] [Related]
37. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial. Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG Eur Urol; 2019 Sep; 76(3):306-312. PubMed ID: 30466891 [TBL] [Abstract][Full Text] [Related]
38. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5. Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115 [TBL] [Abstract][Full Text] [Related]
39. Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer. Josefsson A; Linder A; Flondell Site D; Canesin G; Stiehm A; Anand A; Bjartell A; Damber JE; Welén K Prostate; 2017 Jun; 77(8):849-858. PubMed ID: 28295408 [TBL] [Abstract][Full Text] [Related]
40. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Luo H; Wei W; Ye Z; Zheng J; Xu RH Trends Mol Med; 2021 May; 27(5):482-500. PubMed ID: 33500194 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]